Edward M. Rudnic, Chief Executive Officer

CEO


Ed Rudnic is the CEO of DisperSol. Prior to DisperSol, he served as the CEO of QRx Pharma. Dr. Rudnic was the founder, Chairman and CEO of MiddleBrook Pharmaceuticals. Prior to founding MiddleBrook, he was the Senior Vice President, Development and Technical Operations for Shire Laboratories and held management roles at Merck (Schering-Plough) and at Bristol Myers-Squibb (E.R. Squibb). He is the lead inventor or a co-inventor of 54 issued U.S. patents, and numerous related international patents. Dr. Rudnic holds a B.S. in Pharmacy, a M.S. in Pharmaceutics, and a PhD in Pharmaceutical Sciences from the University of Rhode Island.

Dave A. Miller, PhD

Vice President, Research & Development


Prior to joining DisperSol, Dr. Miller was as a Senior Principal Scientist in the Pharmaceutical and Analytical Research and Development department at Hoffmann-La Roche, Inc. in Nutley, NJ.
Dr. Miller earned his BS in Chemical Engineering and his PhD in Pharmaceutics both from the University of Texas at Austin. His doctoral research was conducted under the supervision of Professors James W. McGinity and Robert O. Williams III. Throughout his career in academia and industry, Dr. Miller’s research focus has been in the area of oral bioavailability enhancement for poorly water-soluble drugs. His expertise includes: amorphous formulation technologies, solid dispersion technologies, solubility enhancement technologies, KinetiSol dispersing, hot-melt extrusion, spray drying, particle engineering technologies, non-sink dissolution testing methodologies, establishing in vitro-in vivo relationships, solid state characterization, physical stability assessment of amorphous systems, and final dosage form design.
Dr. Miller has published numerous peer-reviewed research articles, authored several book chapters, filed multiple patent applications, and is a co-editor of the book Formulating Poorly Water-Soluble Drugs.

Chris Brough, MBA, PhD

Vice President, Technology


Chris is a primary developer of KinetiSol. In 1999, he started a plastics recycling company based on a novel patented process that he invented, a forerunner to KinetiSol. That company was acquired by IntegriCo Composites in 2005. As IntegriCo’s VP of Engineering and Product Development, he led the development and deployment of his technology at IntegriCo and into multiple plastics industry partners. In 2006, Chris met Dave Miller and the two tested the technology for a new application, creating solid amorphous dispersions of pharmaceuticals. Upon successful results, Chris redesigned the equipment for pharmaceutical GMP use and joined Gershon Yaniv to launch DisperSol Technologies in 2007.

Chris holds a BS and MS in mechanical engineering along with an MBA from Brigham Young University and has a PhD in Pharmaceutics from the University of Texas at Austin. His research focused on drug solubility enhancement and abuse deterrent formulation applications of the KinetiSol process.

Justin M. Keen, PhD

Vice President, Operations


Justin has 10 years experience in pharmaceutical formulation development, process development, clinical manufacturing, and process validation. After earning his BS in Chemical Engineering from the University of Texas, Justin worked as a formulation scientist at DPT Laboratories and at PharmaForm, LLC where he gained wide experience in hot melt extrusion, blending, granulation, compression, encapsulation and clinical labeling.

Justin served as the Director of Manufacturing at PharmaForm for 5 years where he oversaw clinical manufacturing, scale up, facility/equipment/process validation, maintenance, and warehousing operations. Justin has supported process development and validation activities for several commercial and generic products and worked with over 30 new chemical entities for numerous formulation development and clinical supply campaigns.

Justin earned his PhD in Pharmaceutics under the supervision of Professor James W. McGinity from the University of Texas at Austin.
Chris holds a BS and MS in mechanical engineering along with an MBA from Brigham Young University and has a PhD in Pharmaceutics from the University of Texas at Austin. His research focused on drug solubility enhancement and abuse deterrent formulation applications of the KinetiSol process.

Raj Sheel, MBA

Vice President, Business Development & Marketing


Raj has over 20 years of experience in business development & marketing across the biotech, pharma & medical device industries. Prior to joining DisperSol, Raj was the Senior Vice President, Corporate Development & Strategy for Orchid Pharma. His experience prior to Orchid includes; head of pharmaceuticals business development for Novavax, Inc., in-licensing lead for ImmunoGen Inc. and head of market research & planning for Smith & Nephew Plc, Endoscopy Division.

Raj has a BS in Biological Sciences from University of Massachusetts-Lowell, an MBA from Babson College and was graduate-trained at MIT in Molecular Neurobiology.